Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

@article{Goicoechea2008GreaterTR,
  title={Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.},
  author={Miguel Goicoechea and Shanshan Liu and Brookie Manning Dugan Best and Shelly Sun and Sonia Jain and Carol Kemper and Mallory Witt and Catherine Diamond and Richard Haubrich and Stan Louie},
  journal={The Journal of infectious diseases},
  year={2008},
  volume={197 1},
  pages={102-8}
}
BACKGROUND Plasma concentrations of tenofovir increase when the drug is coadministered with some ritonavir-boosted protease inhibitors (PI/r). We hypothesized that tenofovir disoproxil fumarate (TDF)-treated patients taking PI/r-based regimens would have a greater decline in renal function than patients receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy. METHODS We compared the estimated decline in renal function among 146 human immunodeficiency virus type 1 (HIV-1… CONTINUE READING